tbuckley/cabot-search huggingface dataset:
Symptomatic Occult Tumor?
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New rules extinguish 'smoking lamp' in growing number of public places
Authors: C. Marwick
Journal: JAMA (1988)

IN ABOUT two weeks, New York City begins strict enforcement of what has been called "the most sweeping nonsmoking law in the United States." It is just one of a growing number of indications that those Americans who continue to smoke in the months and years ahead will find fewer public places to do so. That eventually may include more of those who can't even go home to smoke—the inmates of the nation's jails and prisons. In Utah, for example, the Davis County Jail now is smoke free. The National Commission on Correctional Care, Chicago, says the Davis County sheriff made the decision after studying the experience of the smoke-free jail in Orchard Cove, Wash, noting the legislature's prohibiting of smoking in any general public place, realizing his jail is poorly ventilated, and arranging counseling and medical service for inmates addicted to tobacco. The commission says complaints "have been minimal."
Clinical Lectures on Surgical Subjects. Delivered in University College Hospital.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE "BUGABOO OF THE MAD DOG."
Journal: JAMA (1998)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Potent Activity of a Novel, Irreversible Inhibitor of the Ubiquitin-Proteasome Pathway Against Pre-Clinical Models of Multiple Myeloma.
Authors: Deborah J. Kuhn, Peter M. Voorhees, John S. Strader, Kevin D. Shenk, Congcong M. Sun, Susan D. Demo, Mark K. Bennett, Robert Z. Orlowski
Journal: Blood (2005)
Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4
Authors: Timothy R. Rebbeck, Julie M. Jaffe, Amy H. Walker, Alan J. Wein, S. Bruce Malkowicz
Journal: JNCI Journal of the National Cancer Institute (1998)

Background: Pathways involved in androgen metabolism have been implicated in the etiology of prostate cancer. The goal of this study was to evaluate the effect of CYP3A4, a gene associated with the oxidative deactivation of testosterone, on the clinical presentation of prostate cancers. Methods: A polymerase chain reaction-based approach was used to identify sequence variants of the human CYP3A4 gene. To ascertain whether allelic variants of the CYP3A4 gene were associated with tumor stage and grade and age of the patient at diagnosis, we determined CYP3A4 genotypes in 230 Caucasian men with incident prostate cancer. Results: We identified a novel genetic variant (CYP3A4-V) that has an altered 5′ regulatory element, containing an A to G mutation, upstream of the CYP3A4 gene. We then compared clinical characteristics of prostate cancers in men who did and did not carry this variant. The presence of the CYP3A4-V allele was associated with a higher tumor-lymph node-metastasis (TNM) stage and Gleason grade. The association between CYP3A4 genotype and tumor stage was most pronounced in men diagnosed at a relatively old age who reported no family history of prostate cancer. In this group, 46% of men with stage T3/T4 tumors carried CYP3A4-V, whereas only 5% of individuals with stage T1 tumors carried CYP3A4-V (adjusted odds ratio = 9.45; 95% confidence interval = 2.54–35.17; x2 1 = 12.28; two-sided P<.001). Conclusions: We determined that a single base change in the 5′ flanking region of the CYP3A4 gene was associated with higher clinical stage and grade in men with prostate tumors. Our results suggest that mutations in the CYP3A4 gene may influence prostate carcinogenesis. [J Natl Cancer Inst 1998;90: 1225-9]
短期接触镍导致过敏性接触性皮炎
Authors: M. G. Ahlström, J. P. Thyssen, T. Menné, K. Midander, A. Julander, C. Lidén, C. R. Johnsen, J. D. Johansen
Journal: British Journal of Dermatology (2018)

过敏性接触性皮炎是一种常见的湿疹类型 (可在皮肤接触某种物质时导致炎症)。尽管广为接受皮肤长期接触可导致镍过敏和皮炎, 针对相对短期和重复镍暴露对于镍过敏诱导和引发 (即首次触发) 的意义的探索相对较少, 有人提出皮肤短期接触镍是安全的。丹麦和瑞典进行的一项研究试图检验这一主张, 他们采用的方法是检查皮肤短期重复接触镍是否会引发过敏性接触性皮炎。16 名已知对镍过敏的成人和另外 10 名不过敏的对照受试者 (对照受试者是用于比较的健康个体) 接受了检测。将受试者的各前臂和耳垂暴露于镍和铝片, 共计 3 x 10 分钟。另外,一只手臂提前在封包情况下 (意味着先涂抹溶液,之后用塑料膜或布包裹) 接受 0.5% 月桂醇硫酸酯钠 (SLS) 处理 24 小时。SLS 被添加至洗浴用品和洗涤剂, 以使得它们产生泡沫,是常见的皮肤反应原因。这样做的目的是监测正常或已被 (SLS) 刺激皮肤中镍反应的差异。评估所有镍和铝的部位并测量血流, 因为血流增加可能提示皮肤对镍产生反应。62.5% 的镍过敏受试者在 SLS 处理手臂上对镍产生了反应。暴露于镍的皮肤的血流显著多于暴露于铝皮肤。在镍过敏患者的任何非SLS 镍暴露手臂或任何对照受试者中未见反应或血流的变化。这项研究显示, 相对短期重复接触镍可以在已有镍过敏症的人的受刺激皮肤中引发过敏性接触性皮炎。这些结果支持现行镍管理规定中的限制。 Linked Article:Ahlström et al. Br J Dermatol 2018; 179:1127–1134
Studies on the Mechanism of Benzene Toxicity
Authors: R. Snyder, E. Dimitriadis, R. Guy, P. Hu, K. Cooper, H. Bauer, G. Witz, B. D. Goldstein
Journal: Environmental Health Perspectives (1989)

Using the 59Fe uptake method of Lee et al. it was shown that erythropoiesis in female mice was inhibited following IP administration of benzene, hydroquinone, p-benzoquinone, and muconaldehyde. Toluene protected against the effects of benzene. Coadministration of phenol plus either hydroquinone or catechol resulted in greatly increased toxicity. The combination of metabolites most effective in reducing iron uptake was hydroquinone plus muconaldehyde. We have also shown that treating animals with benzene leads to the formation of adducts of bone marrow DNA as measured by the 32P-postlabeling technique.
Fluorouracil as an Adjuvant to Colorectal Cancer Surgery
Authors: Min C. Li
Journal: JAMA (1977)

<h3>To the Editor.—</h3> I have read Dr C. G. Moertel's comment (236:1935, 1976) emphatically denying the validity of our paper "Chemoprophylaxis for Patients With Colorectal Cancer" with fluorouracil (235:2825, 1976). First, he disputes that the ages of the control and the experimental groups are comparable. Table 1, which is a copy of the published table, will be adequate to show that his argument was an oversight of this table, despite the elegant biostatistical analysis. The percentage of patients beyond 70 years of age is 28.1% in both groups. Secondly, he questions whether the possibilities of improvement of surgical technique or patient care are themajor causes of the observed therapeutic benefits. It is clearly stated in the text that "We are aware of the controversy of study using historical controls vs concurrent, randomized controls. Nevertheless, despite the fact that our control and treated patients were selected in different periods, surgery
Highlights
Journal: JAMA Pediatrics (2018)

Recent work has raised questions about the uniformity of criteria for admission to a neonatal intensive care unit (NICU) and possible overuse of this resource.In this large study in California, 10% of infants born at 34 or more weeks were admitted to a NICU, accounting for 79% of all NICU admissions.Admission rates varied 34-fold across NICUs and there was a 40-fold variation in the reported percentage of high illness acuity.The accompanying Editorial by Goodman and Little discusses the implications of this variation and the need for appropriate population-based data to track variations in care.
SELECTIONS.
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Coordinated Consultant Team for Remote State Hospitals
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Cover
Authors: Ilkka Vartiovaara
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Characterization of potential predictive biomarkers of response to nivolumab in CheckMate 141 in patients with squamous cell carcinoma of the head and neck (SCCHN).
Authors: Fernando Concha-Benavente, Maura L. Gillison, George R. Blumenschein, Kevin Harrington, Jérôme Fayette, A. Dimitrios Colevas, Lisa Licitra, Stefan Kasper, Caroline Even, Francis P. Worden, Nabil F. Saba, Robert I. Haddad, Makoto Tahara, Yasuhisa Hasegawa, Chia-Jui Yen, Mark John Lynch, Manish Monga, William J. Geese, Everett E. Vokes, Robert L. Ferris
Journal: Journal of Clinical Oncology (2017)

6050 Background: Nivolumab, an anti-programmed death-1 (PD-1) monoclonal antibody, demonstrated longer median overall survival (7.5 vs 5.1 months) and improved response (13.3% vs 5.8%) versus investigator choice chemotherapy (ICC) in patients with recurrent SCCHN after platinum failure in CheckMate 141 (NCT02105636), a randomized, open-label Phase 3 trial. We screened peripheral blood lymphocytes (PBL) to identify biomarkers which may predict response to nivolumab. Methods: Paired baseline (day 1) and on treatment (day 43) PBL samples (n = 36; 24 nivolumab; 12 ICC) were analyzed using multicolor flow cytometry and a non-competing anti-PD-1 antibody. Results were correlated with clinical outcome: responders (complete/partial response) and non-responders (stable or progressive disease). Results: Levels of CD8+ T cells at baseline and on treatment were higher in nivolumab responders compared to non-responders (23% vs 13%; P&lt; 0.05). Interestingly, PD-1+ CD8+ and PD-1+ CTLA-4+ CD8+ effector T cells (likely exhausted T cells) decreased about 2-fold following nivolumab in both responders and non-responders ( P&lt; 0.05), whereas, the decrease in CTLA-4+ CD8+ effector T cells following nivolumab was significant in responders only (8% vs 5%; P&lt; 0.05). Levels of PD-1+ TIM-3+ CD8+ effector cells decreased following nivolumab in non-responders only (11% vs 7%; P&lt; 0.05), a similar non-significant reduction was observed in responders. Levels of PD-1+ Tregs were lower in responders than non-responders at baseline (19% vs 33%; P&lt; 0.01), and following nivolumab (12% vs 20%; P&lt; 0.001). As in T-effector cell populations, PD-1+ Tregs decreased about 1.6-fold after nivolumab in both responders and non-responders ( P&lt; 0.01). Interestingly, baseline Ki67+ Treg levels were lower in non-responders (28% vs 17%; P&lt; 0.05). Conclusions: Response to nivolumab may be associated with higher levels of CD8+ T cells and CTLA-4+ CD8+ effector T cells, and lower PD-1+ CD8+ effector T cells and PD-1+ Tregs at baseline. Targeting both PD-1 and CTLA-4 axes is warranted in SCCHN to overcome suppressive signals in CD8+ effector T cells and in Treg cells expressing both checkpoint receptors. Clinical trial information: NCT02105636.
Should epileptics scuba dive?
Authors: J. Thomas Millington
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The Professional Advisory Board of the Epilepsy Foundation of America<sup>1</sup>responded to an inquiry<sup>2</sup>about scuba diving for persons with epilepsy in a recent issue. The Advisory Board of the Epilepsy Foundation of America was of the opinion that the decision as to whether a patient may scuba dive should be made by the individual with epilepsy and not by the examining physician. They also noted that, although there is an increased risk of accident or death in scuba divers, this should be an individual decision. Although one would certainly agree with their concept that the decision whether or not to participate in sports or other activities in life that are hazardous ideally should be an individual one, the examining physician is left with the dilemma as to whether, verbally or in writing, to permit or restrict diving. The patient who suffers from a seizure
Morbidity Surveillance Following the Midwest Flood—Missouri, 1993
Journal: JAMA (1993)

Heavy spring and summer rains during 1993 caused flooding by both the Mississippi and Missouri rivers and by streams in 84 of the 115 counties in Missouri; all 84 were declared federal disaster areas. The Mississippi River attained flood stage during July 15-August 2, and the Missouri River, during July 25-August 2; a total of 2,060,757 acres were submerged, and approximately 60,000 persons throughout Missouri were displaced (National Weather Service, unpublished data, 1993). At the request of the Missouri Department of Health, CDC provided assistance in implementing a surveillance system to monitor flood-related injuries and illnesses in the affected areas. This report presents preliminary findings of these surveillance efforts.
Assessment of the Potential Risk to Workers from Exposure to 1,3-Butadiene
Authors: Duncan Turnbull, Joseph V. Rodricks, Susan M. Brett
Journal: Environmental Health Perspectives (1990)

The available epidemiologic data provide equivocal evidence that 1,3-butadiene is carcinogenic in humans; some available studies suggest that the lymphopoietic system is a target, but there are inconsistencies among studies in the types of tumors associated with 1,3-butadiene exposure, and there is no evidence of a relationship between length of exposure and cancer risk, as one might expect if there was a true causal relationship between 1,3-butadiene exposure and cancer risk. The available chronic animal studies, however, show an increase in tumor incidence associated with exposure to high concentrations of 1,3-butadiene. In addition to the general uncertainty of the relevance of animal data to humans, there are several additional reasons why the National Toxicology Program's mouse study may not be appropriate for assessing possible human risks. These include: a) the possible involvement of a species-specific tumor virus (MuLV) in the response in mice; b) apparent differences between mice and humans in the rate of metabolism of 1,3-butadiene to reactive epoxides that may be proximate carcinogens; c) use of high dose levels that caused excess early mortality; and d) exposure of animals to 1,3-butadiene for only about half their lifetime. While recognizing the uncertainty in using the available animal data for risk assessment, we have performed low-dose extrapolation of the data to examine the implications of the data if humans were as sensitive as rats or mice to 1,3-butadiene, and to examine how the predictions of the animal data compare to that observed in the epidemiologic studies. With the mouse data, because the study was of less than lifetime duration, we have used the Hartley-Sielken time-to-tumor model to permit estimation of lifetime risk from the less than lifetime exposure of the study. With the rat data, we have used three plausible models for assessing low-dose risk: the multistage model, the Weibull model, and the Mantel-Bryan probit model. With both the rat and mouse data, we used information on how much 1,3-butadiene is retained by animals exposed to various concentrations of the chemical. This improves the accuracy of the low-dose extrapolation. When extrapolated to low-dose levels, mice appear to be at greater risk (by a factor of 5-fold to 40-fold) than rats. Some of this difference (a factor 3-fold to 5-fold) may be due to the faster rate of metabolism of 1,3-butadiene to, and higher blood levels of, epoxide derivatives in mice than in rats.(ABSTRACT TRUNCATED AT 400 WORDS)
BERYLLIUM RICKETS
Authors: John G. Hanna
Journal: JAMA (1933)

<h3>To the Editor:</h3> —Your editorial on beryllium rickets in the issue of September 30 completely overlooks—as did the Canadian investigators you cite—a very important fact that may invalidate your conclusions. This is that beryllium has distinct radioactive properties, as has been proved at the California Institute of Technology. The bone lesions observed may indeed resemble rickets, but it would seem that they may also have quite as much resemblance to the bone lesions following the ingestion of minute quantities of radium compounds or other radioactive substances. The alteration in blood plasma may be due, as suggested, to precipitation of phosphates by beryllium ions, but radioactivity is also damaging to blood plasma. Without any intention of reflecting on the work of these investigators, it may be said that the research can hardly be called conclusive, and such a term as "beryllium rickets" cannot be justified until the possible effects of beryllium's